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S10ment. The first considered active monitoring for occult hemorrhage in the gastrointestinal
tract, urinary tract, and brain. Participants generally did not feel that these would be useful in
determining management of children with ITP since serious bleeding was likely to manifest
itself. A single historical paper had suggested that microscopic cranial bleeding may result in
chronic brain disturbance, but overall experience of ITP does not support this. Participants
considered ways of studying this possibility but noted the considerable difficulties in setting up
a formal study and suggested that the established registries should be alerted to capture long-
term data on school performance. The second presentation focused on the extent to which
recent papers are using the new terminology and guidelines. Participants noted the two new
guidelines gave discrepant advice with regard to splenectomy. Management of ITP is not
necessarily straightforward and needs to be tailored to the individual.
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here were two presentations for the session,
‘‘Immune thrombocytopenia (ITP) nomen-
clature, guidelines, and natural history,’’
given by Marc Michel and Adolfo Flores, and a group
of 10 participants discussed the findings.
NATURAL HISTORY
Adolfo Flores challenged physicians managing
patients with ITP to consider monitoring actively for
occult hemorrhage, in particular gastrointestinal bleed-
ing by imaging or testing for occult blood in the feces,
observation for macroscopic or microscopic hematu-
ria, and, very controversially, monitoring for micro-
scopic brain hemorrhage. In addition he presented
data from a literature search on ocular bleeding.
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or a fall in hemoglobin. Testing stools for occult
blood is difficult and may not be reliable, and the
participants were not in favor of looking for this type
of occult bleeding. An important question was raised
concerning whether it is necessary to use H2
receptor antagonists or other protective agents for
patients on corticosteroids irrespective of dose and
duration, since many patients remain on steroids for
longer than first intended. This question has not
been addressed by any of the ITP guidelines. None of
the participants knew if there were any other guide-
lines on this issue. Analysis of the literature suggests
this remains somewhat controversial. The effect of
corticosteroids on induction of peptic ulceration is
disputed,1 but there is some evidence that cortico-
steroids induce mucosal disturbances that predis-
pose to damage by gastric acid. An evaluation of 71
studies (more than 3,000 patients) demonstrated an
increased risk of peptic ulceration and bleeding, and
an association with the dose.2 The increased risk was
small. Clearly the addition of nonsteroidal anti-
inflammatory agents to corticosteroid therapy does
predispose to ulceration and bleeding,3 but this
combination would be contraindicated in ITP. Rou-
tine use of proton pump inhibitors is not generally
recommended.Retinal Hemorrhages
Cases presenting with symptomatic ocular bleed-
ing were discussed. A literature search producedology, Vol 50, No 1, Suppl 1, January 2013, pp S10–S11
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nals, published between 1990 and 2012. These were
mostly individuals who had presented with distur-
bances of vision. This is a very small number in
relation to the incidence of ITP, suggesting that
serious eye hemorrhage is a rare complication.
Two of these cases were in association with intra-
cranial hemorrhage, and in one of these, a 4-year-old
child, this finding was preceded by epileptic seiz-
ures. A 69-year-old man had a known predisposing
eye condition, and one other case described only
subconjunctival bleeding, which is not associated
with serious outcome and is not uncommon in ITP.
Discussion by participants established that routine
fundoscopy for patients with ITP was not performed
by most, but it was agreed that it was important
always to ask for ocular symptoms. One participant,
who always performed simple fundoscopy in
patients (adults and children where possible) pre-
senting with ITP, had never seen retinal hemor-
rhages as part of the acute disease. If retinal
hemorrhages were seen, either because of symptoms
or as part of a routine examination, all participants
agreed that the patient should receive treatment to
raise the platelet count and be referred for urgent
cranial imaging.
Hematuria
The participants were in agreement that ITP
patients of any age who presented with gross hema-
turia should receive treatment to raise the count.
Most participants do not routinely check for micro-
scopic hematuria, but two do and it was suggested
that an audit of this would make an interesting
publishable study to inform future practice.
Microscopic Brain Hemorrhage
A paper from 19714 (discussed by Flores and
Buchanan) reported some children with chronic
ITP with evidence of poor school performance. This
was associated with abnormalities on electroence-
phalogram (EEG). However, this was an isolated
report. No other studies of children with chronic
ITP have reported any long-term neurological prob-
lems, but perhaps follow-up has not been sufficient.
This report was worrying. If there is really evidence
of brain damage, caused by microscopic bleeds, a
change in practice would be required since it would
not be acceptable to recommend ’’no treatment.’’ It
would be very difficult to set up a study for this.
Magnetic resonance or computed tomography brain
imaging would be required on a regular basis, likely
requiring general anesthesia necessary for small
children. In addition, some form of assessment for
clinical evidence of brain dysfunction would berequired, and an age- and sex-matched control group
also matched for lifestyle and activity. This single
paper in the literature demonstrating a somewhat
tenuous link between behaviour and EEG changes
was not felt to be sufficient evidence to pursue this
avenue of research without at least some pointers
from more recent studies. Possibly long-term registry
data may capture this if appropriate questions, such
as evidence about school performance, are included.
The Nordic and UK pediatric registries should be
encouraged to consider this.NOMENCLATURE AND GUIDELINES
Marc Michel presented a review of the literature to
see if there has been appropriate uptake of the new
recommended terminology, and to assess the impact
of the two new guideline papers.5,6 This was a useful
review. The two guidelines are somewhat discrepant
in their advice to clinicians, particularly with regard to
the role of splenectomy. Participants disliked the
recommendation for longer courses of corticosteroids
because of their well-known side effects and dislike
by patients. It was noted that there was no consensus
about what treatment modality to use between
corticosteroids and splenectomy (which should not
be performed before about 12 months from diagno-
sis). Participants agreed that the new thrombopoietin
receptor (TPO)-agonists would probably be used ear-
lier if not so expensive. The management of ITP is not
straightforward and should be tailored to the individ-
ual as has been reinforced by yet another scholarly
review of the management of adults with ITP.7
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